Alzheimer’s has already grabbed attention but plenty of big regulatory decisions still loom for Sarepta, Crispr, Astellas and more.
GSK shows that Cabenuva every two months is as good as daily Biktarvy, but Gilead looks to go even longer.
Research-stage buyouts are as expensive as ever, while commercial assets look to be getting dearer, a new analysis finds.
The UK developer has the launch of what could be the first in a new class of antifungals in its sights.
But pressure is on the shingles vaccine as the consumer spin-off approaches.
The second quarter should bring pivotal data for Karuna and key cardiomyopathy results for Alnylam, while Ionis's eplontersen lags in amyloidosis.
There are long shots and then there is troriluzole. Biohaven will soon find out if it was wise to press on with the asset.